A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Capecitabine/cyclophosphamide (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Acronyms METRO-ABC
- Sponsors Sanofi
- 21 Sep 2017 Planned End Date changed from 15 Sep 2017 to 4 Dec 2017.
- 21 Sep 2017 Planned primary completion date changed from 15 Sep 2017 to 4 Dec 2017.
- 07 Jun 2017 Planned End Date changed from 1 Jun 2017 to 15 Sep 2017.